Pre-treatment T2-weighted MRI texture features can predict NAC response with reasonable accuracy.
Anti-LAT1 monoclonal antibodies significantly inhibited in vitro cell proliferation and in vivo tumor growth of naLAT1/3T3 cells in nude mice, demonstrating LAT1 to be a promising anti-cancer target
These Oncotarget data demonstrate that local delivery of tumor-specific T-cells is an efficient option to convert tumors that are unresponsive to checkpoint inhibitors to permit tumor cures.
The authors developed and analytically validated a new droplet digital PCR -based assay for HPV16 circulating tumor DNA
In 2018, there were over 2 million cases and 0.6 million deaths from breast cancer (BC), making it the most common cancer globally among women.
Cell-free DNA (cfDNA) shed into the blood was discovered in the late 1940s but with rapid advances in genomics and computational analytics in just the past few years, researchers at Georgetown Lombardi Comprehensive Cancer Center now believe that studying tags, or modifications to this type of DNA, may lead to a better understanding of how to assess, and possibly modulate, treatment approaches for cancer and other diseases. Their perspective, drawn from a review of studies to date, appears July 27 in Frontiers in Genetics.
A biomarker that has proven to be a predictor for response to immunotherapies in melanoma patients also has clinical relevance for breast cancer patients, according to a new study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.
New research has identified potential treatment that could improve the human immune system's ability to search out and destroy cancer cells within the body. Scientists have identified a way to restrict the activity of a group of cells which regulate the immune system, which in turn can unleash other immune cells to attack tumours in cancer patients.
Survival rates for adolescents and young adults diagnosed with cancer have varied considerably depending on cancer type. A new study indicates that survival for multiple cancer types in such patients has improved in recent years, but some patients diagnosed with common cancer types still show limited survival improvements. The results are published by Wiley early online in CANCER, a peer-reviewed journal of the American Cancer Society.
A prospective cohort study found that quitting smoking after being diagnosed with early-stage non-small cell lung cancer may slow disease progression and decrease mortality. Given that about half of all smokers continue to smoke after a lung cancer diagnosis, these findings present an opportunity to improve overall and progression-free survival in this type of cancer. The study is published in Annals of Internal Medicine.